Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Aug;32(34):e2002661.
doi: 10.1002/adma.202002661. Epub 2020 Jul 15.

Photoactivatable Protherapeutic Nanomedicine for Cancer

Affiliations
Review

Photoactivatable Protherapeutic Nanomedicine for Cancer

Yan Zhang et al. Adv Mater. 2020 Aug.

Abstract

Therapeutic systems with site-specific pharmaceutical activation hold great promise to enhance therapeutic efficacy while reducing systemic toxicity in cancer therapy. With operational flexibility, noninvasiveness, and high spatiotemporal resolution, photoactivatable nanomedicines have drawn growing attention. Distinct from traditional controlled release systems relying on the difference of biomarker concentrations between disease and healthy tissues, photoactivatable nanomedicines capitalize on the interaction between nanotransducers and light to either trigger photochemical reactions or generate reactive oxygen species (ROS) or heat effect to remotely induce pharmaceutical actions in living subjects. Herein, the recent advances in the development of photoactivatable protherapeutic nanoagents for oncology are summarized. The design strategies and therapeutic applications of these nanoagents are described. Representative examples of each type are discussed in terms of structure, photoactivation mechanism, and preclinical models. Last, potential challenges and perspectives to further develop photoactivatable protherapeutic nanoagents in cancer nanomedicine are discussed.

Keywords: cancer therapy; nanoparticles; photoactivatable nanomedicines; phototherapy; protherapeutics.

PubMed Disclaimer

References

    1. a) L. Zhao, J. Peng, Q. Huang, C. Li, M. Chen, Y. Sun, Q. Lin, L. Zhu, F. Li, Adv. Funct. Mater. 2014, 24, 363;
    1. b) J. Rautio, H. Kumpulainen, T. Heimbach, R. Oliyai, D. Oh, T. Järvinen, J. Savolainen, Nat. Rev. Drug Discovery 2008, 7, 255;
    1. c) R. Duncan, Nat. Rev. Drug Discovery 2003, 2, 347.
    1. R. Singh, J. W. Lillard Jr., Exp. Mol. Pathol. 2009, 86, 215.
    1. a) B. Sumer, J. Gao, Nanomedicine 2008, 3, 137;

LinkOut - more resources